SHR 0302Alternative Names: SHR0302
Latest Information Update: 20 Sep 2016
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Janus kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rheumatoid arthritis
Most Recent Events
- 01 Aug 2016 Jiangsu HengRui Medicine initiates a phase I pharmacokinetics trial in Healthy volunteers in China (PO, Tablet) (NCT02892370)
- 24 Jan 2016 Jiangsu HengRui Medicine plans a phase I trial for Rheumatoid arthritis in China (NCT02665910)
- 01 Apr 2015 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in China (PO) (NCT02423538)